


**Amendment to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (canceled)
2. (currently amended) ~~The compound of Claim 1~~ A compound of the formula Ib:



Ib

wherein the dashed line represents a single or a double bond and wherein

R<sup>1</sup> is selected from:

- (1) -CH(CH<sub>3</sub>)<sub>2</sub>,
- (2) -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>,
- (3) -CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>,
- (4) -cyclopropyl,
- (5) -cyclobutyl,
- (6) -cyclopentyl,
- (7) -CH<sub>2</sub>-cyclopropyl,
- (8) -CH<sub>2</sub>-cyclobutyl,
- (9) -C(CH<sub>3</sub>)<sub>2</sub>(OH),
- (10) -(OH)cyclobutyl,
- (11) -(OH)cyclopentyl,
- (12) -C(CH<sub>3</sub>)<sub>2</sub>(NHCOCH<sub>3</sub>),
- (13) -O-CH<sub>3</sub>,
- (14) -O-CH(CH<sub>3</sub>)<sub>2</sub>,

(15) -S-CH<sub>3</sub>,

(16) -S-CF<sub>3</sub>,










(17) -SO<sub>2</sub>-CH<sub>3</sub>,












(18) -S-CH(CH<sub>3</sub>)<sub>2</sub>,

(19) -SO<sub>2</sub>-CH(CH<sub>3</sub>)<sub>2</sub>,


(20) -NH-SO<sub>2</sub>-CH<sub>3</sub>,

(21) -phenyl,







(42)




(43)



(44)




(45)




(46)




(47)




(48)




(49)



(50)




(51)



(52)




(53)



, and

(54)



and positional and stereo isomers thereof;

R<sup>2</sup> is selected from: (C<sub>0-6</sub>alkyl)-phenyl and (C<sub>0-6</sub>alkyl)-heterocycle, where the alkyl is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

- (a) halo,
- (b) hydroxy,
- (c) -O-C<sub>1-3</sub>alkyl,
- (d) trifluoromethyl,
- (e) -C<sub>1-3</sub>alkyl,
- (f) -CO<sub>2</sub>R<sup>9</sup>, and
- (g) oxo;

and where the phenyl and the heterocycle may be unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

- (a) halo,
- (b) trifluoromethyl,
- (c) trifluoromethoxy,
- (d) hydroxy,
- (e) C<sub>1-6</sub>alkyl,
- (f) C<sub>3-7</sub>cycloalkyl,
- (g) -O-C<sub>1-6</sub>alkyl,
- (h) -O-C<sub>3-7</sub>cycloalkyl,
- (i) -SCF<sub>3</sub>,
- (j) -S-C<sub>1-6</sub>alkyl,
- (k) -SO<sub>2</sub>-C<sub>1-6</sub>alkyl,
- (l) phenyl,
- (m) heterocycle,
- (n) -CO<sub>2</sub>R<sup>9</sup>,
- (o) -CN,
- (p) -NR<sup>9</sup>R<sup>10</sup>,
- (q) -NR<sup>9</sup>-SO<sub>2</sub>-R<sup>10</sup>,
- (r) -SO<sub>2</sub>-NR<sup>9</sup>R<sup>10</sup>,
- (s) -CONR<sup>9</sup>R<sup>10</sup>, and

(t) -O-phenyl;

R<sup>5</sup> is selected from:

- (a) hydrogen,
- (b) hydroxy,
- (c) C<sub>1-6</sub>alkyl,
- (d) C<sub>1-6</sub>alkyl-hydroxy,
- (e) -O-C<sub>1-3</sub>alkyl,
- (f) oxo, and
- (g) halo,
- (h) C<sub>0-4</sub>CO<sub>2</sub>R<sup>9</sup>, and
- (i) CF<sub>3</sub>,

R<sup>15</sup> and R<sup>16</sup> are independently selected from:

- (a) hydrogen,
- (b) halo,
- (c) trifluoromethyl,
- (d) hydroxy,
- (e) C<sub>1-3</sub>alkyl,
- (f) -O-C<sub>1-3</sub>alkyl,
- (g) -CO<sub>2</sub>H,
- (h) -CO<sub>2</sub>C<sub>1-3</sub>alkyl,
- (i) -CN, and
- (j) heterocycle;

and pharmaceutically acceptable salts and individual diastereomers thereof.

3. (canceled)

4. (canceled)

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (canceled)

10. (canceled)

11. (currently amended) The compound of Claim ~~10~~ 2 wherein R<sup>2</sup> is selected from:

- (1) -CH<sub>2</sub>-(phenyl),
- (2) -CH<sub>2</sub>-(4-bromophenyl),
- (3) -CH<sub>2</sub>-(3-chlorophenyl),
- (4) -CH<sub>2</sub>-(3,5-difluorophenyl),
- (5) -CH<sub>2</sub>-((2-trifluoromethyl)phenyl),
- (6) -CH<sub>2</sub>-((3-trifluoromethyl)phenyl),
- (7) -CH<sub>2</sub>-((4-trifluoromethyl)phenyl),
- (8) -CH<sub>2</sub>-((3-trifluoromethoxy)phenyl),
- (9) -CH<sub>2</sub>-((3-trifluoromethylthio)phenyl),
- (10) -CH<sub>2</sub>-((3-trifluoromethoxy-5-thiomethyl)phenyl),
- (11) -CH<sub>2</sub>-((3-trifluoromethoxy-5-methoxy)phenyl),
- (12) -CH<sub>2</sub>-((3-trifluoromethoxy-5-methanesulfonyl)phenyl),
- (13) -CH<sub>2</sub>-((3-trifluoromethoxy-5-amino)phenyl),
- (14) -CH<sub>2</sub>-((3-trifluoromethoxy-5-aminomethanesulfonyl)phenyl),
- (15) -CH<sub>2</sub>-((3-trifluoromethoxy-5-sulfonylamino)phenyl),
- (16) -CH<sub>2</sub>-((3,5-bis-trifluoromethyl)phenyl),
- (17) -CH<sub>2</sub>-((3-fluoro-5-trifluoromethyl)phenyl),
- (18) -CH(CH<sub>3</sub>)-((3,5-bis-trifluoromethyl)phenyl),
- (19) -C(CH<sub>3</sub>)<sub>2</sub>-((3,5-bis-trifluoromethyl)phenyl),
- (20) -CH<sub>2</sub>-(4-(2-trifluoromethyl)pyridyl),
- (21) -CH<sub>2</sub>-(5-(3-trifluoromethyl)pyridyl),

- (22) -CH<sub>2</sub>-(5-(3-trifluoromethyl)pyridazinyl),
- (23) -CH<sub>2</sub>-(4-(2-trifluoromethyl)pyridyl-N-oxide), and
- (24) -CH<sub>2</sub>-(5-(3-trifluoromethyl)pyridyl-N-oxide).

12. (canceled)

13. (canceled)

14. (canceled)


15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. The compound of Claim 1 of the formula:



wherein the dashed line represents a single or a double bond,

R<sup>5</sup> is hydrogen or methyl;

and pharmaceutically acceptable salts and individual diastereomers thereof.



20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)